RSV, COVID and flu
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.
A rise in rates of sudden unexpected infant deaths may have been linked to an off-season surge of RSV in 2021, according to a ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
RSV is the most harmful respiratory illness for young infants, says Dr. Jeffrey Pernica, a professor in the Department of ...